Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• It took more than a decade to diagnose indolent SM in a woman with chronic pain

  The woman lived with abdominal pain for more than a decade before receiving a diagnosis of indolent systemic mastocytosis.

• Experts find several treatments effective in SM-related osteoporosis

  Zoledronic acid, bisphosphonates, IFN-alpha and denosumab appear to prevent fractures and increase BMD in SM patients with osteoporosis.

• Lipid-lowering medications could increase anaphylaxis risk

  Lipid-lowering medications (LLMs) may increase the risk of severe anaphylactic reactions, which would greatly affect patients with SM.

• Patients report SM has a significant effect on their daily lives

  Indolent systemic mastocytosis (ISM) appears to significantly affect activities of daily living in over 50% of patients.

• Avapritinib shows promise in SM in small study

  A new study detailed cellular and other changes resulting from avapritinib therapy for systemic mastocytosis.

• CD30 inhibitor could improve cutaneous mastocytosis, study suggests

  The cellular marker CD30 appears to play a key role in cutaneous mastocytosis, which differs from systemic mastocytosis, a new study says.

• Patients with MCAS may have increased risk of systemic mastocytosis

  Patients with mast cell activation syndrome (MCAS) could require annual controls to detect potential progression to systemic mastocytosis.

• Case report: Patient with SM responds to experimental treatment

  A new case study reported promising results for a man who started experimental therapy for SM symptoms after other treatment failed.

• Market for SM treatments to rise significantly through 2034, new study says

  Increased awareness and diagnosis of SM could increase the growth of the SM pharmaceutical market by 2034.

• Perspectives and challenges in advanced SM management

  A recent study assessed the current state of treatments for advanced systemic mastocytosis and the promise of future ones.